Zydus Initiates Adaptive P-I/II Clinical Study Evaluating its ZyCoV-D Against COVID-19 in India
Shots:
- Zydus has commenced the adaptive P-I/II human clinical trials of its plasmid DNA vaccine- ZyCoV-D and reported its first human dosing
- The Adaptive P-I/II dose escalation study will assess the safety- tolerability- and immunogenicity of the vaccine in ~1000 candidates across multiple clinical sites in India. The company has already manufacture clinical GMP batches of the vaccine candidate for the clinical trials
- ZyCoV-D has demonstrated a strong immune response and a high level of neutralizing Abs in its preclinical studies
Ref: Zydus | Image: The Quint
Related News: Zydus to Initiate Clinical Trials Evaluating ZyCoV-D Vaccine Against COVID-19 in July 2020
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com